Opinions about scientific advances blur party-political lines
By Matthew Nisbet and Ezra Markowitz,
The Conversation
| 02. 19. 2014
Reading about the rapid pace of advances in biomedicine, you may have wondered why more politically liberal countries like Germany and Canada have stronger restrictions on embryonic stem cell research than the politically conservative US.
History and happenstance play a role, but these differences also reflect public concerns that do not conform to traditional left or right political ideologies.
As debates over stem cell research continue and as conflicts over other biomedical advances emerge, a recurring set of questions is likely to be seen. Do scientific breakthroughs promote or undermine social progress? Is research being pursued too cautiously or too quickly? Do scientists respect or cross moral boundaries?
In a study, just published in PLOS ONE, we analysed a series of surveys collected between 2002 and 2010 to better understand what the US public thinks about stem cell research and how they formed these opinions. We were able to distinguish between the different factors influencing their beliefs. At play were factors such as traditional loyalties to political parties and more fundamental beliefs about science and society.
Our results indicate...
Related Articles
By Tomoko Otake, The Japan Times | 04.09.2024
A decade ago, researcher Haruko Obokata caused a sensation when she published two papers in the journal Nature, in which she claimed that she had discovered a way to create stem cells easily using the so-called STAP method.
With STAP...
By Ian Sample, The Guardian | 03.08.2024
Scientists are a step closer to making IVF eggs from patients’ skin cells after adapting the procedure that created Dolly the sheep, the first cloned mammal, more than two decades ago.
The work raises the prospect of older women being...
By Ramon Antonio Vargas, The Guardian | 02.28.2024
Doctors say a man in California who contracted blood cancer while living with HIV is in remission from both potentially fatal illnesses thanks to a treatment they are hailing as remarkable and encouraging.
Paul Edmonds is only the fifth-known person...
By Victoria Gray, Uduak Thomas, and Kevin Davies, The CRISPR Journal | 02.14.2024
In July 2019, medical staff in Nashville dosed the first U.S. patient in the exa-cel therapy trial, sponsored by Vertex Pharmaceuticals and CRISPR Therapeutics. That first patient was Victoria Gray, a mother of four from Forest, Mississippi, a sickle cell...